Seres Therapeutics Statistics Share Statistics Seres Therapeutics has 8.75M
shares outstanding. The number of shares has increased by 0.27%
in one year.
Shares Outstanding 8.75M Shares Change (YoY) 0.27% Shares Change (QoQ) 0.17% Owned by Institutions (%) 35.26% Shares Floating 6.46M Failed to Deliver (FTD) Shares 17,633 FTD / Avg. Volume 9.7%
Short Selling Information The latest short interest is 936.25K, so 10.69% of the outstanding
shares have been sold short.
Short Interest 936.25K Short % of Shares Out 10.69% Short % of Float 17.38% Short Ratio (days to cover) 2.47
Valuation Ratios The PE ratio is 18990.89 and the forward
PE ratio is -1.86.
Seres Therapeutics's PEG ratio is
-189.72.
PE Ratio 18990.89 Forward PE -1.86 PS Ratio 0 Forward PS 6.6 PB Ratio 187.37 P/FCF Ratio -17.34 PEG Ratio -189.72
Financial Ratio History Enterprise Valuation Seres Therapeutics has an Enterprise Value (EV) of 2.64B.
EV / Sales 0 EV / EBITDA -23.8 EV / EBIT -17.79 EV / FCF -17.74
Financial Position The company has a current ratio of 0.94,
with a Debt / Equity ratio of 6.65.
Current Ratio 0.94 Quick Ratio 0.94 Debt / Equity 6.65 Debt / EBITDA -0.83 Debt / FCF -0.62 Interest Coverage 0
Financial Efficiency Return on Equity is 0.99% and Return on Invested Capital is -104.64%.
Return on Equity 0.99% Return on Assets 0.1% Return on Invested Capital -104.64% Revenue Per Employee n/a Profits Per Employee $1.32K Employee Count 103 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by 2.99% in the
last 52 weeks. The beta is 0.16, so Seres Therapeutics's
price volatility has been higher than the market average.
Beta 0.16 52-Week Price Change 2.99% 50-Day Moving Average 16.65 200-Day Moving Average 13.77 Relative Strength Index (RSI) 55.33 Average Volume (20 Days) 181,755
Income Statement
Revenue n/a Gross Profit -14.7M Operating Income -121.31M Net Income 136K EBITDA -111.07M EBIT -125.77M Earnings Per Share (EPS) 0
Full Income Statement Balance Sheet The company has 30.79M in cash and 91.64M in
debt, giving a net cash position of -60.85M.
Cash & Cash Equivalents 30.79M Total Debt 91.64M Net Cash -60.85M Retained Earnings -978.1M Total Assets 143.8M Working Capital 17.75M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -148.61M
and capital expenditures -380K, giving a free cash flow of -148.99M.
Operating Cash Flow -148.61M Capital Expenditures -380K Free Cash Flow -148.99M FCF Per Share -0.96
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields MCRB does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield 0.01% FCF Yield -5.77%
Dividend Details Analyst Forecast The average price target for MCRB is $15,
which is -20.8% lower than the current price. The consensus rating is "Hold".
Price Target $15 Price Target Difference -20.8% Analyst Consensus Hold Analyst Count 4
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number 0.04 Graham Upside -99.79%
Stock Splits The last stock split was on Apr 22, 2025. It was a
backward
split with a ratio of 1:20.
Last Split Date Apr 22, 2025 Split Type backward Split Ratio 1:20
Scores Altman Z-Score -11.02 Piotroski F-Score 5
